Form 4: Co-Diagnostics CEO Reports Stock Transactions

Dwight H. Egan, CEO of Co-Diagnostics, Inc., reported transactions involving restricted stock units and common stock.

Summary

• Dwight H. Egan, Chief Executive Officer and Director of Co-Diagnostics, Inc. (CODX), filed a Form 4 detailing stock transactions.
• On May 23, 2026, 4,584 shares of common stock were acquired at $0.00, bringing the total beneficially owned to 29,526.
• Also on May 23, 2026, 1,633 shares of common stock were disposed of at $5.07 per share, reducing the total beneficially owned to 27,893.
• The acquisition of 4,584 shares is related to restricted stock units (RSUs) awarded under the company's 2015 Long Term Incentive Plan.
• These RSUs vest in six equal installments every six months, with vesting commencement dates in November 2023, November 2024, and November 2025.
• The disposition of 1,633 shares represents the number of shares sold to cover tax withholding obligations upon the vesting of RSUs, a mandatory 'sell to cover' transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transactions are routine for RSU vesting and tax obligations, with no indication of discretionary selling or buying.

Positives

• The acquisition of 4,584 shares indicates continued equity awards to the CEO under the long-term incentive plan, aligning management's interests with shareholders.
• The CEO's beneficial ownership remains substantial at 27,893 shares after the reported transactions.

Negatives

• The disposal of 1,633 shares, even if for tax withholding, represents a reduction in the CEO's direct holdings.

Risks

• The 'sell to cover' transaction for tax withholding obligations, while standard, can be perceived negatively by the market as it reduces the CEO's net share count.
• Future vesting of RSUs may lead to further 'sell to cover' transactions, potentially impacting share availability.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The disposition of 1,633 shares 'does not represent a discretionary trade by the Reporting Person' and is mandated by the Issuer's election for 'sell to cover' transactions to satisfy tax withholding obligations.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The 'sell to cover' mechanism for RSU vesting is a common practice across the tech and biotech industries to manage tax liabilities without requiring the executive to fund the taxes out-of-pocket.

Stakeholder Impact

• Shareholders: The transactions are routine and do not suggest a change in the CEO's long-term commitment to the company. The 'sell to cover' is a standard mechanism.
• Employees: The RSU awards and vesting reflect the company's incentive plans for key personnel.
• Management: The CEO's equity holdings are adjusted due to standard tax withholding procedures.

Next Steps

• Continued vesting of restricted stock units according to the specified schedules.
• Potential future 'sell to cover' transactions for tax withholding obligations as RSUs vest.

Key Dates

Keywords

Form 4, SEC Filing, Co-Diagnostics, CODX, Dwight H. Egan, Stock Transaction, Restricted Stock Units, RSU Vesting, Beneficial Ownership, Insider Trading, Tax Withholding